Can a single dose of the human papilloma virus (HPV) vaccine prevent oropharyngeal cancer?

The incidence of human papillomavirus (HPV)-related head and neck squamous cell carcinomas has been rising.1,2 Clinicians treating patients with oropharyngeal cancer strongly support the Joint Committee on Vaccination and Immunisation recommendation3 on gender-neutral vaccination to prevent anal, cervical, oropharyngeal, and penile cancer. However, although the HPV vaccines were initially tested and approved in triple-dose regimens,4 there is evidence to support a single-dose vaccination schedule to optimise population uptake and provide some coverage.
Source: The British Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Tags: Editorial Source Type: research